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Abstract
Twenty pituitary adenomas, surgically removed from patients suffering from acromegaly, were studied. The tumours were immunosta-
ined with anti-GH and anti-PRL antibodies and with antibodies raised against particular subtypes of somatostatin receptors (rsst1–5).
Expression of rsst immunoreactivity was scored using the following scale: 0 — negative reaction, 1 — weak reaction, 2 — moderate
reaction, 3 — strong reaction. In 15 patients in whom the GH response to the acute administration of 200 ug octreotide was tested the
correlation between the expression of rsst and the percentage of GH drop was estimated. All the tumours were GH-immunopositive and
in the majority (14/20) co-expression of PRL was also found. All the adenomas examined expressed rsst2A (20/20) and rsst5 (12/12) receptor
proteins. Receptors sst2B and rsst3 were found in all but one of the tumours examined (19/20 and 11/12, respectively). None of tumours
investigated presented rsst4 immunopositivity. The mixed (GH/PRL) adenomas showed a tendency to a higher expression of rsst2A +
+ rsst2B and a greater response to octreotide administration. A significant positive correlation was found between rsst2A + rsst2B expres-
sions and a drop in GH after octreotide.
To conclude, the GH-inhibiting effect of octreotide depends on the intensity of expression of both rsst2A and rsst2B. Both isoforms of rsst2
mediate the same biological response (inhibition of GH secretion) in GH-secreting and GH/PRL-secreting adenomas.
(Pol J Endocrinol 2008; 59 (3): 196–199)
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Streszczenie
Zbadano 20 gruczolaków przysadki, usuniętych operacyjne u chorych z akromegalią. Na skrawkach parafinowych guzów wykonano
odczyny immunohistochemiczne z użyciem przeciwciał anty-GH i anty-PRL oraz przeciwciał przeciwko poszczególnym podtypom re-
ceptorów somatostatynowych (rsst1–5). Nasilenie odczynu na rsst oceniano z użyciem następującej skali: 0 — odczyn negatywny,
1 — odczyn słaby, 2 — odczyn umiarkowany, 3 — odczyn silny. U 15 chorych zbadano korelacje między nasileniem odczynów na rsst
a odpowiedzią GH na podanie 200 mg oktreotydu. Wszystkie badane guzy były immunopozytywne dla GH, a większość wykazywała
także ko-ekspresję PRL (14/20). Wszystkie badane gruczolaki wykazywały ekspresję rsst2A (20/20) i rsst5 (12/12). Receptory sst2B i rsst3
występowały także we wszystkich badanych guzach poza jednym (odpowiednio: 19/20 i 11/12). W żadnym z badanych w tym kierunku
guzów nie stwierdzono obecności rsst4. Mieszane gruczolaki (GH/PRL) wykazywały tendencje do wyższej ekspresji rsst2A + rsst2B
i zarazem silniejszej odpowiedzi na oktreotyd, niż guzy monohormonalne. Stwierdzono znamienną korelację dodatnią między sumą
ekspresji rsst2A + rsst2B a spadkiem GH po podaniu oktreotydu. Podsumowując, hamujący wydzielanie GH efekt oktreotydu zależy od
nasilenia ekspresji receptorów sst2A i sst2B. Obie izoformy receptora sst2 w guzach wydzielających hormon wzrostu pośredniczą w tej
samej odpowiedzi biologicznej (hamowaniu wydzielania GH). (Endokrynol Pol 2008; 59 (3): 196–199)
Słowa kluczowe: akromegalia, receptory somatostatynowe, oktreotyd
This paper was financially supported by the Medical University of Łódź.
Introduction
Inhibition of growth hormone (GH) secretion was the
first known physiological effect of somatostatin. Because
acromegaly is a disease caused by excess of GH, long-
acting somatostatin analogues were soon introduced to
treat it. In the 1990s the five subtypes of somatostatin
receptor were cloned (for review see: 1). Moreover, one
subtype (sst2) exists in two splicing variants, called 2A
and 2B, and it was suggested that these two variants
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may mediate different biological effects [2, 3]. It was
shown that inhibition of GH secretion by somatostatin
is mediated by subtypes 2 and 5 [4], although the role
of subtype 1 cannot be excluded [5]. Long-acting soma-
tostatin analogues applied in the medical treatment of
acromegaly, octreotide and lanreotide bind preferen-
tially to the receptor subtype 2. Earlier studies on so-
matostatin receptors in GH-secreting pituitary adeno-
mas showed the expression of mostly sst2 and sst5
[6–10] The expression of sst1 and sst3 was variable, and
sst 4 was only detected in one study [6]. However, the
majority of published studies concerned the expression
of receptors at the level of mRNA and not at the level of
receptor proteins. The aim of the present study was to
re-evaluate the data on somatostatin receptors in GH-
secreting adenomas by means of immunohistochemi-
stry and to answer the question concerning the rela-
tionship between receptor protein expression and re-
sponsiveness to the long-acting somatostatin analogue
octreotide.
Material and methods
Twenty pituitary adenomas, surgically removed from
patients suffering from acromegaly, were studied. The
tumours were immunostained with antibodies against
the pituitary hormones (GH, PRL, LH, FSH, TSH, free-
alpha SU, ACTH). To detect particular subtypes of so-
matostatin receptor (rsst1–5) we used primary antibo-
dies raised against the specific regions of sst receptor
proteins and obtained from Gramsch Laboratories
(Schwabhausen, Germany). The expression of rsst im-
munoreactivity was scored using the following scale:
0 — negative reaction, 1 — weak reaction, 2 — modera-
te reaction, 3 — strong reaction. In 15 patients the effect
of the GH response to the acute administration of octre-
otide was tested. Octreotide (Sandostatin Novartis) was
administered subcutaneously in a dose of 200 ug and
GH concentration in the blood serum were measured
just before the injection (0’) and after 60’, 120’, and 240’.
The maximal drop was expressed as a percentage of the
basal value. The correlation between the expression sco-
re of rsst and the percentage GH drop was assessed
using Pearson’s coefficient of correlation and analysed
by a t-test.
Results
All the tumours investigated were GH-immunopositi-
ve. In the majority of tumours (14/20) co-expression of
PRL was also found. Moreover, LH was co-expressed
in 4 adenomas, TSH in 2, FSH in one and free-alpha SU
also in one tumour. All the adenomas examined expres-
sed rsst2A (20/20) and rsst5 (12/12) receptor proteins.
Receptors sst2B and rsst3 were found in all but one of
the tumours (19/20 and 11/12, respectively). None of the
tumours presented rsst4 immunopositivity. The mixed
(GH/PRL) adenomas showed a tendency towards higher
expression of rsst2A + rsst2B (4.32 ± 0.28 vs. 3.65 ±
±  0.61, means ± SEM) and a greater response to octre-
otide administration (respective values of GH level drop
= 85.8 ± 4.1% vs. 53.6 ± 8.1%). However, these diffe-
rences were not statistically significant, probably becau-
se of the low number of cases secreting GH alone in our
material. A significant positive correlation was found
between the summarised score of rsst2A + rsst2B
expressions and the drop in GH after octreotide admi-
nistration (Fig. 1). The tendencies towards a positive
correlation between the summarised score of rsst2A +
+ rsst2B + rsst3 + rsst5 (Fig. 2) and towards a negative
correlation between rsst2A/rsst2B expression ratio (Fig. 3)
and the octreotide effect were also observed.
Discussion
As in the earlier studies [11–13] we found that the ma-
jority of pituitary adenomas express not only GH but
also PRL and, less frequently, glycoprotein hormones.
Results of our immunohistochemical study on the
expression of somatostatin receptors in pituitary ade-
nomas excised in patients with acromegaly show a pre-
valence of rsst2 and rsst5 and are concordant with ear-
lier observations cited in the Introduction. They also
Figure 1. Correlation between the summarised score of
rsst2A+rsst2B expression and the drop in GH after octreotide
administration
Rycina 1. Korelacja między sumą ekspresji rsst2A+rsst2B
a zmniejszeniem stężenia GH po podaniu okreotydu
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show that the GH-inhibiting effect of octreotide de-
pends on the intensity of expression of both rsst2A and
rsst2B. Recently it has been shown that the response to
octreotide (both in vivo and in vitro) is positively corre-
lated with the immunohistochemical expression of
rsst2A [14]. However, expression of rsst2B was not esti-
mated in this study. Alderton et al. [2] showed that CHO
cells transfected with different isoforms of rsst2 diffe-
rentially responded to somatostatin in vitro. The rsst2A
variant mediated growth inhibition, whereas rsst2B
exerted the opposite effect. In our earlier study on hu-
man non-functioning pituitary adenoma cells in vitro
we observed similar effects. We showed that the expres-
sion of rsst2A (but not rsst2B) correlated positively with
the inhibitory effect of somatostatin on tumoural cell
viability [15] or chromogranin A and alpha-subunit se-
cretions [3]. The results of the present study do not sup-
port the hypothesis concerning the opposite effects of
the A and B variants of rsst2 with respect to the control
of GH secretion. It is evident that both isoforms of rsst2
mediate the same biological response (inhibition of GH
secretion) in GH-secreting and GH/PRL-secreting ade-
nomas. However, we cannot exclude the possibility that
these opposite effects of rsst2 isoforms may concern the
antiproliferative action in these adenomas. Further stu-
dy is needed to answer this question.
The question of whether the hormonal phenotype
of pituitary adenomas in acromegalic patients detected
by means of the immunohistochemical investigation is
related to rsst expression and somatostatin analogue ef-
fectiveness remains unclear. However, the observations
made in this study suggest that co-expression of PRL may
be accompanied by a higher expression of both isoforms
of rsst2 and a stronger inhibitory response to octreotide.
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